Account
Inquiry
Amble Tirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed for metabolic research applications. This 39-amino acid peptide features two non-natural residues (Aib at positions 2 and 13) and a C20 fatty diacid side chain at Lys20, contributing to its extended half-life of approximately 117 hours.
The compound functions by mimicking endogenous incretins to enhance insulin secretion, suppress glucagon levels, delay gastric emptying, and reduce appetite. These mechanisms make Amble Tirzepatide particularly interesting for studies involving glycemic control and weight management.
In clinical research settings, typical administration protocols begin with 2.5mg weekly doses, with potential escalation to 5mg after 4 weeks. Subsequent 2.5mg increments may be implemented every 4 weeks based on study requirements, with a maximum research dose of 15mg weekly.
Amble Tirzepatide is supplied as a lyophilized powder in sterile vials, requiring reconstitution with appropriate solvents before experimental use. The product maintains stability when stored properly at controlled temperatures.
Our manufacturing process employs advanced peptide synthesis techniques with rigorous quality control measures including HPLC, mass spectrometry, and amino acid analysis to ensure batch-to-batch consistency and purity. The product is suitable for in vitro and in vivo research applications.
Important Note: This product is intended for research use only by qualified professionals in laboratory settings. Not for human consumption or diagnostic use.
